Scoping Review Assesses Active Surveillance Systems for Antivirals and Corticosteroids in COVID-19
How Hospitals Tracked COVID Drug Risks in Real Time
This scoping review analyzed 15 publications from 9,183 literature records to evaluate active surveillance systems for COVID-19 medications …
This study shows how doctors tracked COVID drug safety in real time, helping patients get safer care during a crisis.
Systematic review identifies specific medications significantly associated with drug-induced hyperpigmentation across diverse drug classes.
These Common Meds Might Be Darkening Your Skin
A systematic review and meta-analysis evaluated twenty-two studies regarding the incidence of drug-induced hyperpigmentation. The analysis f…
A major review reveals many common medicines can cause noticeable skin darkening.
Oral tofacitinib monotherapy with fire needling induced marked regression of cutaneous Rosai-Dorfman disease lesions in a single patient.
A pill and a heated needle tamed a stubborn face disease
This case report and literature review describes a 55-year-old female with refractory cutaneous Rosai-Dorfman disease who failed prior thera…
A woman whose face was covered in stubborn red nodules finally saw improvement when doctors tried a surprising combination that crossed medi…
Systematic review links neutrophil extracellular trap dysregulation to pregnancy complications
Web of White Blood Cells Linked to Pregnancy Risks
A systematic review of emerging evidence indicates that dysregulation of neutrophil extracellular trap (NET) formation and clearance is stro…
A sticky web of white blood cells meant to fight germs can instead trigger serious pregnancy risks like preeclampsia and preterm birth when …
Hydroxychloroquine did not prevent SLE progression in incomplete lupus patients in randomized trial
Hydroxychloroquine did not slow disease progression in incomplete lupus patients over two years
A randomized, double-blind trial of 180 patients with incomplete lupus erythematosus found hydroxychloroquine did not reduce progression to …
Hydroxychloroquine failed to slow lupus progression in patients with early symptoms over two years, matching placebo results.
Phase 2 trial finds hydroxychloroquine does not prevent rheumatoid arthritis in at-risk individuals
Hydroxychloroquine did not prevent rheumatoid arthritis in at-risk individuals in trial
In a phase 2 randomized controlled trial of 144 individuals at risk for rheumatoid arthritis with elevated anti-CCP3 antibodies, 12 months o…
A new trial found that taking hydroxychloroquine for a year did not stop people at high risk for rheumatoid arthritis from developing the di…